Ly-M003
Wilson Disease
Lingyi Biotech Co., Ltd.Phase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Wilson Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ZINC ACETATE Nobelpharma | Phase 4 | BBB |
Teta 4Hcl Orphalan | Phase 3 | BBB |
ZINC D-GLUCONATE (1:2) Jun Li | Phase 4 | BBB |
Trientine Excelsior | Phase 3 | BB |
Penicillamine Orphalan | Phase 3 | BB |
View all 21 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →